Cesca’s SurgWerks Platform is a vision for the future of regenerative medicine that enables a complete therapy delivered at point of care. Our pipeline of therapies target vascular disease with an integrated system for the harvesting, processing and delivery of autologous stem cells to the patient in less than 2 hours.
The CellWerks Platform is a solution for intra-laboratory bioprocessing and analysis of blood cells for clinical applications. Based on our patented AutoXpress® technology, CellWerks delivers a functionally closed system for concentrating hematopoietic stem cells in under one hour.
January, 2016 interview with Cesca Therapeutics’ CEO Robin Stracey
Robin Stracey discusses the Company’s approach to regenerative medicine with autologous stem cells.